Principal Investigator Heinrich Heine University Düsseldorf (HHU) and University Hospital Düsseldorf (UKD) Project

Project: “Development of a novel clincally applicable lipase inhibitor for personalised treatment of triple negative breast cancer and pancreatic ductal adenocarcinoma”

Background:
Triple-negative breast cancer (TNBC) and pancreatic ductal ardenocarcinoma (PDAC) are extraordinarily aggressive cancers characterised by early and fast metastasis. Treatment options are limited and presonalised strategies missing.
Tumor cells show an altered lipid metabolism to support fast growth and metastasis. A promising inhibitor target is the lysosomal acid  lipase (LAL) with high activity in TNBC and PDAC cells.

canSERV services:
Knud’s lab has established an activity-based LAL inhibitor screening set-up and canSERV enables to transfer this set-up to a high-throughput facility in the Center of Molecular Medicine in Oslo, Norway. In addition a high-quality compound library, containing 100,000 substances, is provided by canSERV partner EU-OPENSCREEN.

Societal Impact:
The societal impact lies in the chance to expand the repertoire to find personalised treatment strategies for individual patients and increase their chances of survival.